Compounds > n-3-methylbutyl-n-1-methylacetonylnitrosamine

Page last updated: 2024-12-06

n-3-methylbutyl-n-1-methylacetonylnitrosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-3-methylbutyl-N-1-methylacetonylnitrosamine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	51227
CHEBI ID	191527
MeSH ID	M0074861

Synonyms (19)

Synonym
2-butanone, 3-((3-methylbutyl)nitrosoamino)-
mambna
3-((isopentyl)nitrosoamino)-2-butanone
brn 5924833
n-3-methylbutyl-n-1-methylacetonylnitrosamine
n-3-methylbutyl-n-1-methyl acetonylnitrosamine
2-butanone, 3-((isopentyl)nitrosoamino)-
71016-15-4
3-[(3-methylbutyl)nitrosoamino]-2-butanone
n-(3-methylbutyl)-n-(3-oxobutan-2-yl)nitrous amide
CHEBI:191527
AKOS006278427
n-1-methylacetonyl-n-3-methylbutyl-nitrosamine
3-[(3-methylbutyl)(nitroso)amino]butan-2-one
n-nitroso-n-(1-methyl-2-oxopropyl)-3-methyl-1-butanamine
3-((3-methylbutyl)nitrosoamino)-2-butanone
n-nitroso-n-(1-methylacetonyl)-3-methylbutylamine
n-nitroso-n-1-methylacetonyl-n-3-methylbutylamine
DTXSID40991322

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" A dose-response relationship of cell number reduction was observed at certain dose range."	( [Effects of nitrosamine on in vitro cultured human esophageal epithelial cells]. Pei, XF, 1990)	0.28

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
nitrosamine	N-Nitroso amines, compounds of the structure R2NNO. Compounds RNHNO are not ordinarily isolable, but they, too, are nitrosamines. The name is a contraction of N-nitrosoamine and, as such, does not require the N locant.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	9 (90.00)	18.7374
1990's	1 (10.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.88 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	4.28 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.88)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	1.96	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
diethylnitrosamine Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.	2.37	2	0	nitrosamine	carcinogenic agent; hepatotoxic agent; mutagen
dimethylnitrosamine Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.	1.95	1	0	nitrosamine	geroprotector; mutagen
isoamylamine isoamylamine: RN given refers to parent cpd. isopentylamine : A primary aliphatic amine that is butan-1-amine carrying a methyl substituent at position 3.	1.96	1	0	primary aliphatic amine	bacterial metabolite; plant metabolite
nitrosobenzylmethylamine nitrosobenzylmethylamine: structure	1.95	1	0
sodium nitrite Sodium Nitrite: Nitrous acid sodium salt. Used in many industrial processes, in meat curing, coloring, and preserving, and as a reagent in ANALYTICAL CHEMISTRY TECHNIQUES. It is used therapeutically as an antidote in cyanide poisoning. The compound is toxic and mutagenic and will react in vivo with secondary or tertiary amines thereby producing highly carcinogenic nitrosamines.. sodium nitrite : An inorganic sodium salt having nitrite as the counterion. Used as a food preservative and antidote to cyanide poisoning.	2.37	2	0	inorganic sodium salt; nitrite salt	antidote to cyanide poisoning; antihypertensive agent; antimicrobial food preservative; food antioxidant; poison

Condition	Indicated	Relationship Strength	Studies	Trials
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	0	2.37	2	0
Cancer of Lung [description not available]	0	2.37	2	0
Experimental Neoplasms [description not available]	0	1.96	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	2.37	2	0
Cancer of Esophagus [description not available]	0	1.95	1	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	0	1.95	1	0
Adenoma, Basal Cell [description not available]	0	1.96	1	0
Carcinoma, Epidermoid [description not available]	0	2.37	2	0
Hepatocellular Carcinoma [description not available]	0	1.96	1	0
Cancer of Liver [description not available]	0	1.96	1	0
Papilloma, Squamous Cell [description not available]	0	2.37	2	0
Cancer of Stomach [description not available]	0	2.37	2	0
Adenoma A benign epithelial tumor with a glandular organization.	0	1.96	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	2.37	2	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	1.96	1	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	0	1.96	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	1.96	1	0
Papilloma A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)	0	7.37	2	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	0	2.37	2	0